Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;14(11):e70120.
doi: 10.1002/brb3.70120.

A Remedy for Crime? A Systematic Review on the Effects of Pharmacological ADHD Treatment on Criminal Recidivism and Rehabilitation in Inmates With ADHD

Affiliations

A Remedy for Crime? A Systematic Review on the Effects of Pharmacological ADHD Treatment on Criminal Recidivism and Rehabilitation in Inmates With ADHD

A Carlander et al. Brain Behav. 2024 Nov.

Abstract

Introduction: There is a high prevalence of attention-deficit/hyperactivity disorder (ADHD) in prison populations compared to the general population, and ADHD has also been shown to be associated with criminality and antisocial behavior. This systematic review examines the effect of pharmacological ADHD treatment on criminal recidivism, ADHD symptoms, and rehabilitation in inmates with ADHD.

Methods: Adhering to PRISMA 2020 and AMSTAR guidelines, we conducted a structured search on September 6, 2023 using PubMed. We focused on original research published in peer-reviewed scientific journals, following the IMRaD format, written in English, containing the established search terms, based on participants who met the criteria for ADHD diagnosis (any edition of DSM), and who were incarcerated at the start of pharmacological treatment for ADHD. The primary outcome was criminal recidivism, the secondary outcomes were ADHD symptoms, and rehabilitation-related factors such as global function, norm-breaking/antisocial behavior, adaptation to society/institutional behavior, cognitive function, and well-being.

Results: Five studies, based on three patient cohorts, were included in this systematic review. Surprisingly, only one study investigated criminal recidivism. That study indicated that self-reported criminal recidivism was lower than expected among inmates who had received pharmacological ADHD treatment. The five studies showed varying results in the effectiveness of pharmacological ADHD treatment on ADHD symptoms and other rehabilitation-related factors. The included studies also varied regarding participant characteristics, study design, dosage, adherence to treatment, treatment regimes, and measured outcomes. All studies reported using osmotic-release oral system (OROS) methylphenidate as their drug of choice.

Conclusion: We conclude that there is limited empirical evidence to support the efficacy of pharmacological ADHD treatment on criminal recidivism in inmates diagnosed with ADHD. Still, evidence suggests that these treatments can reduce ADHD symptoms and enhance rehabilitation outcomes, which may, in turn, lower the rate of reoffending. We point to the need for more targeted research in this area.

Keywords: ADHD; criminal recidivism; methylphenidate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only. *Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). **If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

References

    1. American Psychiatric Association . 2013. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Washington, DC: American Psychiatric Publishing. 10.1176/appi.books.9780890425596. - DOI
    1. Asherson, P. , Buitelaar J., Faraone S. V., and Rohde L. A.. 2016. “Adult Attention‐Deficit Hyperactivity Disorder: Key Conceptual Issues.” Lancet Psychiatry 3, no. 6: 568–578. 10.1016/S2215-0366(16)30032-3. - DOI - PubMed
    1. Asherson, P. , Johansson L., Holland R., et al. 2022. “OROS‐Methylphenidate to Reduce ADHD Symptoms in Male Prisoners Aged 16–25 Years: A RCT.” Efficacy and Mechanism Evaluation 9, no. 6. 10.3310/THEI8200. - DOI - PubMed
    1. Asherson, P. , Johansson L., Holland R., et al. 2023. “Randomised Controlled Trial of the Short‐Term Effects of Osmotic‐Release Oral System Methylphenidate on Symptoms and Behavioural Outcomes in Young Male Prisoners With Attention Deficit Hyperactivity Disorder: CIAO‐II Study.” British Journal of Psychiatry 222, no. 1: 7–17. 10.1192/bjp.2022.77. - DOI - PMC - PubMed
    1. Baggio, S. , Fructuoso A., Guimaraes M., et al. 2018. “Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta‐Analysis.” Front Psychiatry 9: 331. 10.3389/fpsyt.2018.00331. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources